Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Current Status of Transarterial Chemoembolization (Tace) Agents in Hepatocellular Carcinoma Treatment Publisher



Saghafian Larijani R1 ; Shabani Ravari N1 ; Goodarzi N2 ; Akhlaghpour S3 ; Saghafian Larijani S4 ; Rouini MR5 ; Dinarvand R1, 2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Nanotechnology Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, 1417614315, Iran
  3. 3. Pardis Noor Medical Imaging Center, Iran
  4. 4. Research and Clinical Development Center of Firoozabadi Hospital, Iran University of Medical Sciences, Tehran, Iran
  5. 5. Biopharmaceutics and Pharmacokinetics Division, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Drug Delivery Science and Technology Published:2022


Abstract

Primary liver cancer is among the most common fatal solid cancers, ranking as the fourth most frequent cause of cancer-related mortality worldwide. Hepatocellular carcinoma (HCC) is the most prevalent histological type of primary liver cancers, which accounts for up to 90% of cases and is resistant to a large percentage of currently available anti-cancer drugs. Amongst various therapeutic options, transarterial chemoembolization (TACE) is an efficient option in patients with the intermediate stage of HCC. Commercially, different embolients enable clinicians to perform TACE. Embolic materials include gelatin sponge, degradable starch microspheres (DSMs) and calibrated microspheres. This article reviews commercially available materials used in the TACE procedure and evaluates their pros and cons in this regard. © 2022 Elsevier B.V.
Related Docs
1. Advanced Therapeutic Modalities in Hepatocellular Carcinoma: Novel Insights, Journal of Cellular and Molecular Medicine (2021)
2. Engineered Plga Microspheres for Extended-Release of Naltrexone: In Vitro, In Vivo, and Ivivr, Pharmaceutical Development and Technology (2023)
3. Circulating Tumor Dnas and Non-Coding Rnas As Potential Biomarkers for Hepatocellular Carcinoma Diagnosis, Prognosis and Response to Therapy, Hepatoma Research (2019)
4. Neutrophil-To-Lymphocyte Ratio As an Index of Treatment Response to Trans-Arterial Chemoembolization in Hepatocellular Carcinoma, Gastroenterology and Hepatology from Bed to Bench (2024)
5. Inter-Reader Agreement of Recist and Mrecist Criteria for Assessing Response to Transarterial Chemoembolization in Hepatocellular Carcinoma, BMC Medical Imaging (2025)
6. A Comprehensive Review About the Utilization of Immune Checkpoint Inhibitors and Combination Therapy in Hepatocellular Carcinoma: An Updated Review, Cancer Cell International (2022)
7. Preparation, Characterization and Evaluation of Drug Release Properties of Simvastatin-Loaded Plga Microspheres, Iranian Journal of Pharmaceutical Research (2016)
Experts (# of related papers)
View all Related Experts
Rassoul Dinarvand (2)
Reza Masaeli (1)